Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Strategic Co-Development Partnership with Lantheus for Aus

Monday, December 30, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced a strategic co-development partnership with Lantheus for the Australian market. This collaboration aims to enhance the development of their therapeutic programs, particularly focusing on the BetaBart (RV-01) clinical study. The company has received IND approval from the US FDA to initiate Phase I studies targeting B7H3, marking a significant advancement in their research efforts.
Price reaction · baseline $5 (2024-12-30T16:43:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
-4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Strategic partnership with Lantheus enhances development capabilities.
  • Positive clinical updates across multiple programs indicate progress.
  • IND approval from FDA marks a significant milestone.

Full Press Release Details

• Announcements
• Price Sensitive
• December 30, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• January 10, 2022
• Announcements
• February 25, 2022
• Announcements
• March 28, 2023
• Announcements
• August 31, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of the partnership with Lantheus?

The partnership aims to enhance the development of therapeutic programs in Australia.

What clinical study is Radiopharm focusing on?

Radiopharm is focusing on the BetaBart (RV-01) clinical study.

What approval did Radiopharm receive from the FDA?

Radiopharm received IND approval to initiate Phase I studies targeting B7H3.

When was the partnership with Lantheus announced?

The partnership was announced on December 30, 2024.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Lantheus BetaBart clinical study FDA IND approval
Last updated: Dec 30, 2024